In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to ...
Children and young adults to benefit after NICE recommends personalised immunotherapy to treat blood cancer be made routinely available on the NHS ...
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
Cabozantinib with nivolumab is recommended as an option for untreated advanced renal cell carcinoma in adults, only if: their disease is intermediate or poor risk as defined in the International ...
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee B. Committee members from committee A, committee C and committee D also took part ...
The committee recommended that future renal cell carcinoma trials should be sufficiently powered to analyse differences in treatment effect by risk group (see section 1.9). The committee highlighted ...
The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps.
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results